Naima Moustaid-Moussa Selected Research

Uncoupling Protein 1

12/2021	Uncoupling protein 1-independent effects of eicosapentaenoic acid in brown adipose tissue of diet-induced obese female mice.
10/2021	Sex-Dependent Effects of Eicosapentaenoic Acid on Hepatic Steatosis in UCP1 Knockout Mice.
1/2019	Eicosapentaenoic Acid Reduces Adiposity, Glucose Intolerance and Increases Oxygen Consumption Independently of Uncoupling Protein 1.
1/2019	Fish Oil Protects Wild Type and Uncoupling Protein 1-Deficient Mice from Obesity and Glucose Intolerance by Increasing Energy Expenditure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naima Moustaid-Moussa Research Topics

Disease

44	Inflammation (Inflammations) 01/2022 - 11/2010
43	Obesity 10/2022 - 05/2003
25	Insulin Resistance 10/2022 - 04/2005
9	Glucose Intolerance 12/2021 - 04/2005
7	Body Weight (Weight, Body) 06/2022 - 01/2006
7	Breast Neoplasms (Breast Cancer) 03/2022 - 01/2018
4	Atherosclerosis 03/2021 - 01/2016
4	Hyperglycemia 03/2021 - 11/2006
4	Type 2 Diabetes Mellitus (MODY) 01/2021 - 09/2010
4	Neoplasms (Cancer) 01/2020 - 01/2018
4	Hypertrophy 01/2019 - 12/2012
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2022 - 01/2019
3	Weight Gain 01/2022 - 11/2010
3	Chronic Disease (Chronic Diseases) 10/2021 - 01/2014
3	Metabolic Diseases (Metabolic Disease) 01/2021 - 09/2013
2	Fatty Liver 01/2021 - 01/2019
2	Weight Loss (Weight Reduction) 01/2020 - 11/2018
2	Non-alcoholic Fatty Liver Disease 03/2019 - 01/2019
2	Hyperlipidemias (Hyperlipidemia) 01/2019 - 01/2016
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 01/2007
2	Hypertension (High Blood Pressure) 03/2009 - 04/2005
1	AIDS-Related Complex (ARC) 03/2022
1	Neoplasm Metastasis (Metastasis) 02/2022
1	Dysbiosis 01/2022
1	Heart Diseases (Heart Disease) 01/2022
1	Peripheral Nervous System Diseases (PNS Diseases) 03/2021
1	Liver Diseases (Liver Disease) 01/2020
1	Alzheimer Disease (Alzheimer's Disease) 01/2020
1	Osteoarthritis 01/2020
1	Post-Exercise Hypotension 08/2019
1	Dyslipidemias (Dyslipidemia) 03/2019

Drug/Important Bio-Agent (IBA)

22	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 04/2005
11	Insulin (Novolin)FDA Link 10/2022 - 01/2006
11	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 04/2005
9	Eicosapentaenoic AcidIBA 12/2021 - 11/2010
9	AdipokinesIBA 01/2019 - 11/2010
8	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 10/2021 - 10/2017
8	LipidsIBA 10/2021 - 01/2013
6	AngiotensinogenIBA 10/2022 - 03/2009
6	Proteins (Proteins, Gene)FDA Link 02/2022 - 05/2003
6	Messenger RNA (mRNA)IBA 10/2021 - 04/2005
6	MicroRNAs (MicroRNA)IBA 10/2021 - 10/2017
5	PolyphenolsIBA 01/2021 - 04/2013
5	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2020 - 01/2018
5	CytokinesIBA 01/2020 - 02/2012
5	Triglycerides (Triacylglycerol)IBA 01/2019 - 11/2006
5	AdiponectinIBA 01/2018 - 01/2006
4	LeptinIBA 06/2022 - 01/2006
4	Hormones (Hormone)IBA 02/2022 - 12/2019
4	Fish OilsIBA 01/2022 - 01/2019
4	Uncoupling Protein 1IBA 12/2021 - 01/2019
4	CholesterolIBA 01/2020 - 04/2005
3	CurcuminIBA 11/2021 - 01/2014
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 10/2021 - 01/2012
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2019 - 05/2003
3	ResistinIBA 01/2019 - 01/2006
2	Angiotensin IIIBA 10/2022 - 01/2020
2	Captopril (Capoten)FDA LinkGeneric 10/2022 - 11/2019
2	PhytochemicalsIBA 03/2022 - 10/2019
2	ResveratrolIBA 10/2021 - 01/2014
2	C-PeptideIBA 03/2021 - 12/2018
2	AntioxidantsIBA 01/2021 - 10/2019
2	Anthocyanins (Anthocyanin)IBA 10/2020 - 10/2019
2	Transcription Factors (Transcription Factor)IBA 10/2020 - 01/2020
2	TocotrienolsIBA 01/2020 - 01/2019
2	Leukotriene B4IBA 01/2020 - 01/2019
2	TeaIBA 01/2019 - 01/2014
2	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2017 - 12/2013
2	ReninIBA 01/2012 - 03/2009
2	IsoflavonesIBA 09/2010 - 01/2007
2	Type 2 Angiotensin ReceptorIBA 03/2009 - 04/2005
1	Dietary Fats (Dietary Fat)IBA 06/2022
1	Adenosine Triphosphate (ATP)IBA 03/2022
1	cinnamaldehyde (cinnamic aldehyde)FDA Link 03/2022
1	arctigeninIBA 03/2022
1	Chlorogenic AcidIBA 03/2022
1	Superoxides (Superoxide)IBA 03/2022
1	lipopolysaccharide-binding proteinIBA 01/2022
1	Olanzapine (Zyprexa)FDA Link 01/2022
1	GlucuronidesIBA 11/2021
1	Therapeutic UsesIBA 03/2021
1	Amino Acids FDA Link 01/2021
1	Angiotensin Receptor AntagonistsIBA 01/2021
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2020
1	annattoIBA 01/2020
1	Caspase 1 (ICE Protease)IBA 01/2020
1	CCAAT-Enhancer-Binding Protein-betaIBA 01/2020
1	InflammasomesIBA 01/2020
1	Small Interfering RNA (siRNA)IBA 01/2020
1	oxidized low density lipoproteinIBA 01/2020
1	Conditioned Culture MediaIBA 01/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2019
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 11/2019
1	Mitochondrial Uncoupling ProteinsIBA 01/2019

Therapy/Procedure

4	Therapeutics 03/2021 - 03/2019
3	Bariatric Surgery 11/2018 - 01/2013
1	Euthanasia (Mercy Killing) 01/2022
1	Intravenous Administration 10/2021
1	Chemoprevention 01/2019